The Technical Analyst
Galapagos NV [GLPG]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Galapagos NV Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-1.06% $28.91
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 905.09 mill |
| EPS: | -0.0600 |
| P/E: | -481.83 |
| Earnings Date: | May 02, 2024 |
| SharesOutstanding: | 65.90 mill |
| Avg Daily Volume: | 0.126 mill |
| RATING 2024-04-18 |
|---|
| B+ |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Buy | |
| Return On Asset: | Strong Buy | |
| DE: | Neutral | |
| P/E: | Buy | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -481.83 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -81.97x |
| Company: PE -481.83 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-20.40 (-170.55%) $-49.31 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 28.25 - 29.57 ( +/- 2.27%) |
| ATR Model: 14 days |
Forecast:
16:00 - $28.94
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $28.94
Forecast 2: 16:00 - $28.94
Forecast 3: 16:00 - $28.94
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $28.91 (-1.06% ) |
| Volume | 0.138 mill |
| Avg. Vol. | 0.126 mill |
| % of Avg. Vol | 109.41 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GLPG
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $39.10 | N/A | Active |
|---|
GLPG
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Last 10 Buy Signals
Latest Press Releases
2024-04-04 16:01:00 - Press Release
Galapagos Showcases Innovative Approach In Hematological Cancer Care With Clinical And Translational Data Presentations At Ebmt Congress 2024
Two oral presentations and one poster on encore preliminary data from phase 1/2 cd19 car-t studies in non-hodgkin lymphoma (nhl) and chronic lymphocytic leukemia (cll) / richter transformation (rt)
2024-03-28 16:01:00 - Press Release
Galapagos Publishes 2023 Annual Report And Announces Annual And Extraordinary Shareholders' Meetings
Mechelen, belgium; 28 march 2024, 21.01 cet; regulated information – galapagos nv (euronext & nasdaq: glpg) today publishes its annual report for the financial year 2023 and announces its annual and extraordinary shareholders' meetings (agm and egm) to be held sequentially on tuesday, 30 april 2024 at 2:00 pm (cet) and 3:00 pm (cet), respectively, at the registered office of the company.
2024-03-26 16:01:00 - Press Release
Galapagos Appoints Andrew Dickinson As Non-executive Non-independent Director To Its Board
Mechelen, belgium; 26 march 2024, 21:01 cet; galapagos nv (euronext & nasdaq: glpg) today announced that during its meeting of 26 march 2024, the board of directors appointed mr. dickinson as non-executive non-independent director by way of cooptation.
2024-02-22 16:01:00 - Press Release
Galapagos Announces Full Year 2023 Results And Outlook For 2024
Full year 2023 key financials : group net revenues of €783.5 million, including jyseleca® net sales of €112.3 million cash and current financial investments of €3.7 billion on 31 december 2023 operational cash burn i of €414.8 million, within guidance 2023 and year-to-date key updates : transferred jyseleca® business, including approximately 400 positions, to alfasigma s.p.a. achieved encouraging data from ongoing phase 1/2 studies with cd19 car-t product candidates, glpg5101 in rrnhl and glpg5201, in rrcll, with or without rt expanded car-t pipeline with start of phase 1/2 study with bcma car-t product candidate glpg5301 in rrmm enrolled first patients in phase 2 study with tyk2 inhibitor, glpg3667, in dm and sle for strategic reasons, it was decided not to continue development of cd19 car-t candidate in rsle expanded point-of-care car-t network in the u...
2024-02-15 16:01:00 - Press Release
Galapagos Presents At Ebmt-eha Annual Meeting 2024
Showcases meaningful advances in decentralized car t-cell manufacturing and presents translational and clinical data from ongoing phase 1/2 cd19 car-t studies
Latest News
2024-04-03 10:36:09 - Zacks Investment Research
After Plunging -7.94% in 4 Weeks, Here's Why the Trend Might Reverse for Galapagos (GLPG)
The heavy selling pressure might have exhausted for Galapagos (GLPG) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
2024-03-18 10:36:06 - Zacks Investment Research
Down -14.35% in 4 Weeks, Here's Why Galapagos NV (GLPG) Looks Ripe for a Turnaround
Galapagos NV (GLPG) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
2023-12-15 09:46:51 - Zacks Investment Research
Buy These 4 Low-Beta Stocks to Counter Market Volatility
It is imperative to build a portfolio of low-beta stocks to sail through a volatile market. Virco Mfg (VIRC), Galapagos NV (GLPG), Axonics (AXNX) and Stride (LRN) are well-poised to gain.
2023-12-13 07:32:03 - Zacks Investment Research
New Strong Buy Stocks for December 13th
TZOO, GLPG, BBVA, TW and STNE have been added to the Zacks Rank #1 (Strong Buy) List on December 13, 2023.
2023-11-05 09:14:09 - Seeking Alpha
Galapagos NV (GLPG) Q3 2023 Earnings Call Transcript
Galapagos NV (NASDAQ:GLPG ) Q3 2023 Earnings Conference Call November 3, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CFO & COO Jeevan Shetty - Head of Clinical Development, Oncology Conference Call Participants Xian Deng - UBS Dane Leone - Raymond James Johoon Kim - RBC Capital Markets Jason Gerberry - Bank of America Sebastiaan van der Schoot - Kempen Jacob Mekhael - KBC Securities Operator Good day, and thank you for standing by. Welcome to the Galapagos Q3 2023 Financial Results Conference Call.
2023-08-04 16:30:18 - Seeking Alpha
Galapagos NV (GLPG) Q2 2023 Earnings Call Transcript
Galapagos NV (NASDAQ:GLPG ) Q2 2023 Results Conference Call August 4, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Head, IR Paul Stoffels - CEO, Chairman, Interim Head, R&D Thad Huston - CFO and COO Michele Manto - Chief Commercial Officer Daniele D'Ambrosio - Head of Immunology Conference Call Participants Emily Field - Barclays Jason Gerberry - Bank of America Mike Ulz - Morgan Stanley Brian Balchin - Jefferies Xian Deng - UBS Phil Nadeau - TD Cowen Dane Leone - Raymond James Sebastiaan van der Schoot - Kempen Jacob Mekhael - KBC Securities Operator Good day and thank you for standing by. Welcome to the Galapagos H1 2023 Financial Results Conference Call.
2023-05-06 01:59:04 - Seeking Alpha
Galapagos Stands Strong On Jyseleca Positive Clinical Data
Galapagos' focuses on immunology and oncology, with its flagship Jyseleca being used to treat rheumatoid arthritis and ulcerative colitis in Europe and Japan. The company is also developing CAR-T therapies with encouraging initial safety and efficacy data presented from ongoing Phase 1/2 studies.
2023-02-24 10:35:02 - Seeking Alpha
Galapagos NV (GLPG) Q4 2022 Earnings Call Transcript
Galapagos NV (NASDAQ:GLPG ) Q4 2022 Earnings Conference Call February 24, 2023 8:00 AM ET Company Participants Sofie Van Gijsel - Senior Director of Investor Relations Paul Stoffels - Chief Executive Officer Bart Filius - Chief Operating Officer & President Daniele D'Ambrosio - Head of Immunology Michele Manto - Chief Commercial Officer Conference Call Participants Phil Nadeau - Cowen Peter Verdult - Citi Brian Abrahams - RBC Capital Markets Rosie Turner - Jefferies Dane Leone - Raymond James Suzanne van Voorthuizen - Kempen Operator Good day and thank you for standing by. Welcome to the Galapagos Full Year 2022 Financial Results Call and Webcast.
2023-02-11 07:07:14 - Seeking Alpha
Galapagos: Crohn's Disease Trial Failure, Still Maintaining A Buy Rating
On February 8th, 2023, Galapagos announced disappointing results of their phase 3 DIVERSITY Crohn's disease study; the company is no longer planning to file an MAA. Galapagos stock fell 8%, and the stock is still hovering around negative $2.0Bn enterprise value territory.
2023-02-09 08:35:00 - Market Watch
Galapagos shares down after announcing clinical-trial miss for Crohn's disease
U.S.-listed shares of Galapagos GLPG, +0.41% were down 8.9% in premarket trading on Thursday, the day after the company said an experimental treatment for Crohn's disease missed the primary endpoints in a Phase 3 clinical trial. The drug, filgotinib, is approved to treat rheumatoid arthritis and ulcerative colitis in Europe and Japan.